使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good afternoon, ladies and gentlemen, and welcome to Baxter's International second-quarter 2015 earnings conference call.
各位女士、各位先生,下午好,歡迎參加百特國際(Baxter International)2015 年第二季財報電話會議。
(Operator instructions)
(接線員指示)
As a reminder, this call is being recorded by Baxter, and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. If you have any objections, please disconnect at this time.
提醒各位,本次電話會議由百特錄音,並受著作權保護。未經百特許可,不得錄音或轉播。如您有任何異議,請於此時中斷連線。
I would now like to turn the call over to Ms. Claire Trachtman, Vice President, Investor Relations at Baxter International. Ms. Trachtman, you may begin.
現在我想將電話會議交給百特國際投資人關係副總裁 Claire Trachtman 女士。Trachtman 女士,您可以開始。
- VP of IR
- VP of IR
Thanks, Stephanie.
謝謝你,Stephanie。
Good afternoon, and welcome to our second-quarter 2015 earnings conference call. Joining me today are Bob Parkinson, CEO and Chairman of Baxter International, Jay Saccaro, Chief Financial Officer, and Scott Bohaboy, Corporate Vice President, Investor Relations and Treasurer.
各位下午好,歡迎參加我們 2015 年第二季財報電話會議。今天與我一同出席的有百特國際執行長兼董事長 Bob Parkinson、財務長 Jay Saccaro,以及企業副總裁(投資人關係與財務長)Scott Bohaboy。
On the call this afternoon, we will be discussing Baxter's second-quarter financial results and outlook for the remainder of 2015, before taking your questions. I would like to take a moment to highlight that our second-quarter results are inclusive of the BioScience business, as the official spin-off of Baxalta occurred subsequent to the close of the quarter on July 1.
今天下午的電話會議中,我們將在回答各位提問之前,先討論百特第二季財務結果以及 2015 年剩餘期間的展望。我想先提醒各位,我們第二季的結果包含 BioScience(生物科學)事業,因為 Baxalta 的正式分拆是在 7 月 1 日、也就是本季結束後才完成。
Going forward, the financial outlook and results for Baxter will be reported on a standalone basis, excluding the BioScience business. On the call today, we will focus the discussion on the performance of new Baxter, as Baxalta will host a conference call tomorrow to provide additional highlights on their performance in the second quarter, and outlook for the remainder of the year. We plan to post standalone new Baxter financial schedules for the quarterly periods of 2014, and the first half of 2015 to our Investor Relations website, prior to our third-quarter earnings release, to enable year-over-year comparison.
展望未來,百特的財務展望與業績將以獨立公司基礎揭露,不再包含 BioScience 事業。今天的電話會議我們將聚焦於「新百特」的表現;Baxalta 將於明天召開電話會議,提供其第二季表現與今年剩餘期間展望的更多重點。為便於年度對比,我們計畫在第三季財報發布前,於投資人關係網站上張貼 2014 年各季及 2015 年上半年「新百特」獨立財務明細表。
So with that, let me start our prepared remarks, by reminding you that this presentation including comments regarding our financial outlook, new product development, and regulatory matters contain forward-looking statements that result involved risks and uncertainties. And, of course, our actual results could differ materially from our current expectations. Please refer to today's press release and our SEC filings for more detail, concerning factors that could cause actual results to differ materially.
接下來我開始我們的事先準備發言。提醒各位,本簡報包含有關我們財務展望、新產品開發及法規事項的評論,均屬前瞻性陳述,涉及風險與不確定性。當然,我們的實際結果可能與目前預期有重大差異。請參閱今日新聞稿及我們向美國證券交易委員會(SEC)提交的文件,以取得可能導致實際結果與預期有重大差異之因素的更多細節。
In addition on today's call, non-GAAP financial measures will be used to help investors understand Baxter's ongoing business performance. A reconciliation of non-GAAP financial measures being discussed today, to the comparable GAAP financial measures is included in our earnings release issued this afternoon, and available on our website.
此外,在今天的電話會議中,我們將使用非 GAAP 財務衡量指標,以協助投資人了解百特持續營運的業務表現。今日所討論之非 GAAP 財務衡量指標與可比 GAAP 財務衡量指標的調節表,已包含於我們今天下午發布的財報新聞稿中,並可於我們網站取得。
Now I'd like to turn the call over to Bob Parkinson.
現在我想把電話會議交給 Bob Parkinson。
- Chairman & CEO
- Chairman & CEO
Thank you, Claire. Good afternoon, and thanks to all of you for joining us.
謝謝你,Claire。各位下午好,感謝各位加入我們。
Today's call is a transitional event for Baxter. It comes on the heels of our successful spin-off of Baxalta. The excitement level continues to build at the new Baxter, as we embark on our journey as a standalone entity, and begin to implement a number of the new strategic initiatives, and margin improvement actions that will accelerate our profitable growth in the years ahead.
今天的電話會議對百特而言是一個過渡性的里程碑事件。這是在我們成功分拆 Baxalta 之後緊接著舉行。隨著我們以獨立實體展開旅程,並開始推動多項新的策略性倡議與改善毛利的行動,以加速未來數年的獲利成長,「新百特」的振奮情緒持續升溫。
For the second quarter, Baxter delivered a strong performance, with adjusted earnings of $1.00 per diluted share, exceeding our previous earnings guidance of $0.92 to $0.96 per diluted share. Worldwide sales also exceeded our guidance, increasing 3% on a constant currency basis. And after adjusting for the impact of increased US competition for cyclophosphamide, sales advanced 4%.
第二季百特交出強勁表現,調整後每股稀釋盈餘為 1.00 美元,高於我們先前提供的每股稀釋盈餘指引 0.92 至 0.96 美元。全球銷售額亦超越指引,以固定匯率計算成長 3%。若再調整美國市場環磷醯胺(cyclophosphamide)競爭加劇的影響,銷售額成長 4%。
Certainly, our biggest milestone for both the quarter and the year was the successful completion of the BioScience spin-off, resulting in the establishment of two leading global healthcare companies. The smooth transition that we've seen following the spin is a credit to the comprehensive planning, and disciplined execution carried out by employees and leaders across both businesses. And our strong second-quarter results provide both Baxter and Baxalta with positive momentum, as we continue our commitment to enhance value for all of our stakeholders.
當然,本季以及今年最大的里程碑,是成功完成 BioScience 事業分拆,進而建立兩家領先的全球醫療保健公司。分拆後我們所見到的平順過渡,歸功於兩個事業體的員工與領導團隊所進行的周延規劃與嚴謹執行。而我們第二季的強勁成果,也為百特與 Baxalta 帶來正向動能,讓我們能持續致力於為所有利害關係人提升價值。
As we laid out at our investor conference in May, accelerating profitable growth is critical to Baxter's future success, and is an objective that the entire management team is focused on. We are not only striving to meet our profit growth goals, but frankly, we are aiming to exceed them. Rebasing our cost structure, optimizing the existing portfolio and launching numerous high-value differentiated products are the three focus areas that we will execute against over the long-range plan to drive the financial goals that we provided in May.
正如我們在 5 月投資人會議中所說,加速獲利成長對百特未來成功至關重要,也是整個管理團隊專注的目標。我們不僅努力達成獲利成長目標,坦白說,我們的目標是超越它們。重塑成本結構、優化既有產品組合,以及推出多項高價值差異化產品,是我們在長期計畫中將執行的三大重點領域,以推動我們在 5 月所提供的財務目標。
Many of these initiatives have been launched, and are gaining traction. So with this as a backdrop, I would like to highlight some of our recent achievements. First, addressing our standalone cost structure is crucial to meet our goal of increasing earnings, at a rate meaningfully faster than sales growth, and we're making progress on a number of fronts.
其中許多倡議已經啟動,並正逐步展現成效。在此背景下,我想強調我們近期的一些成果。首先,因應獨立後的成本結構對達成我們「盈餘成長速度顯著快於銷售成長」的目標至關重要,而我們在多個面向都正取得進展。
The Gambro integration program continues to advance. We are on track to capture $100 million of cost synergies in 2015, and as we exit the year we will have successfully achieved two-thirds of our $300 million 2017 cost synergy target. And more broadly, a comprehensive cost rebasing plan for Baxter is now underway, and we are executing on key opportunities to reduce structural costs, and increase efficiencies across the global enterprise. Now that the spin is complete, we started to implement a number of substantive measures, and look forward to sharing more information on these initiatives as we progress.
Gambro 整合計畫持續推進。我們有望在 2015 年實現 1 億美元的成本綜效;而在年底時,我們將成功達成 2017 年 3 億美元成本綜效目標的三分之二。更廣泛而言,百特全面性的成本重塑計畫現已展開,我們正針對降低結構性成本與提升全球企業效率的關鍵機會加以落實。隨著分拆完成,我們已開始推行多項實質措施,並期待在推進過程中分享更多相關資訊。
With respect to portfolio management, during the quarter we took steps to optimize our global supply of IV solutions to address demand, while also improving profitability. In May, we received FDA approval establishing in our Sabinanigo, Spain facility as an approved manufacturing site for saline for the US market. The FDA is also in the process of reviewing our application to source saline from our manufacturing site in Cuernavaca, Mexico.
在產品組合管理方面,本季我們採取措施以優化靜脈輸液(IV)解決方案的全球供應,以因應需求,同時提升獲利能力。5 月,我們取得 FDA 核准,將西班牙 Sabinanigo 廠納入可為美國市場生產生理食鹽水的核准製造據點。FDA 也正在審查我們的申請,以便從墨西哥 Cuernavaca 製造據點供應生理食鹽水。
As all of you are aware, saline has been listed in drug shortage databases, as maintained by the FDA over the past two years. So introducing a new supply from Spain, and potentially Mexico, for the US market will provide us greater flexibility to respond to market demand. It also reflects our commitment to ensuring that we are optimizing our global supply, and allocating or reallocating products to markets that generate enhanced returns aligned with our margin improvement goals.
各位都知道,過去兩年來,生理食鹽水一直被列入 FDA 維護的藥品短缺資料庫。因此,為美國市場引入來自西班牙、以及未來可能來自墨西哥的新供應來源,將使我們在回應市場需求時更具彈性。這也反映我們致力於最佳化全球供應,並將產品配置或重新配置至能帶來更高報酬、且符合我們改善毛利目標的市場。
Finally I want to share some recent highlights from our new product pipeline. As you've heard, the leadership team emphasized at our Investor conference, innovation is Baxter's lifeblood, and fundamental to sustained growth. We have an exceptional pipeline that's well-balanced among highly advanced new products, meaningful improvements to our existing offerings, and expanding our portfolio into new geographies. All are focused on improving the quality of care, while addressing key areas of medical need.
最後,我想分享我們新產品研發管線的一些近期亮點。正如各位所聽到的,領導團隊在投資人會議上強調,創新是百特的命脈,也是持續成長的根本。我們擁有卓越的研發管線,在高度成熟的新產品、對既有產品的重大改良,以及將產品組合拓展至新地理市場之間取得良好平衡。所有項目都聚焦於提升照護品質,同時滿足關鍵醫療需求領域。
So some recent milestones include, in our hospital products business, the full-scale launch of the next-generation SIGMA Spectrum Infusion pump is now underway in the US, Puerto Rico and Canada, and I am pleased to report that demand is strong. The Spectrum platform has been honored with the best in KLAS customer satisfaction award for four consecutive years, and the latest generation pump includes several innovative features, including an enhanced Master Drug library, which helps to reduce pump-related adverse drug events and improve patient safety.
近期的一些里程碑包括:在我們的醫院產品事業中,下一代 SIGMA Spectrum 輸注幫浦已在美國、波多黎各與加拿大展開全面上市,我很高興地報告需求強勁。Spectrum 平台已連續四年獲得 KLAS 客戶滿意度最佳獎項肯定;最新一代幫浦包含多項創新功能,包括強化版主藥品資料庫(Master Drug library),可協助降低與幫浦相關的不良用藥事件並提升病人安全。
Customer response has been very positive, and the SIGMA Spectrum is currently being used, or in the process of being placed in six of the top seven hospital systems in the United States, as ranked by US News & World Report.
客戶回饋非常正面,而 SIGMA Spectrum 目前已在美國《US News & World Report》排名前七大醫院體系中的六家投入使用,或正處於導入部署流程中。
In our renal business, we initiated the launch of our AK98 in-center hemodialysis monitor in several markets in Eastern and Central Europe, the Middle East and Africa. The AK series is our flagship in-center HD monitor, and this latest version offers advantages in usability and reliability, while reducing the total cost of operation.
在我們的腎臟業務方面,我們已在東歐與中歐、中東及非洲的多個市場啟動 AK98 院內血液透析監測儀的上市。AK 系列是我們院內 HD 監測儀的旗艦產品,而此最新版本在易用性與可靠性方面具備優勢,同時可降低總營運成本。
In the US, we completed a 510(k) submission with the FDA for AMIA, our next-generation peritoneal dialysis cycler, now integrated with our SHARESOURCE web-based connectivity platform. AMIA incorporates user-friendly features like a graphical touchscreen interface, along with secure two-way connectivity that lets healthcare providers remotely monitor treatment, and adjust prescriptions as necessary.
在美國,我們已就 AMIA(我們的下一代腹膜透析循環機)向 FDA 完成 510(k) 申報;該產品現已與我們的 SHARESOURCE 網路式連線平台整合。AMIA 具備圖形化觸控螢幕介面等友善功能,並提供安全的雙向連線,使醫療照護提供者可遠端監測治療,並視需要調整處方。
And finally, I am also excited to share that the FDA has approved Baxter's Investigational Device Exemption for our VIVIA home-based hemodialysis system. This milestone helps clear the way for the final US study. And as we previously shared, the VIVIA technology has the potential to transform home hemodialysis, and allow more patients to benefit from high dose HD in their homes.
最後,我也很高興分享,FDA 已核准 Baxter 針對我們 VIVIA 居家血液透析系統的研究性器材豁免(Investigational Device Exemption)。此一里程碑有助於為最終的美國研究掃除障礙。此外,如同我們先前所分享,VIVIA 技術有潛力改變居家血液透析,並讓更多病患能在家中受益於高劑量 HD。
These are just a few of the new products that we'll bring to market over the next several years. Our pipeline is well-positioned to make a meaningful impact on both near- and longer-term performance, and I look forward to providing more details on the progress and potential of this pipeline going forward. So with that, I will now turn the call over to Jay, for a discussion of our second quarter results and outlook for the remainder of the year. And then, I'd like to make some closing comments, before then opening up the call to Q&A.
以上只是我們未來幾年將推向市場的新產品中的一部分。我們的產品研發管線已具備良好布局,可對近期與中長期的業績表現帶來實質影響;我也期待未來就此管線的進展與潛力提供更多細節。接下來,我將把電話會議交給 Jay,請他說明我們第二季的業績結果,以及今年剩餘期間的展望。之後,在開放問答之前,我也想做一些結語。
Jay, please?
Jay,請?
- CFO
- CFO
Thanks, Bob, and good afternoon, everyone.
謝謝你,Bob,各位下午好。
As Bob mentioned, adjusted earnings in the second quarter of $1.00 per diluted share exceeded our previously issued guidance range of $0.92 to $0 96 per share. GAAP earnings of $0.60 per diluted share included net after-tax special items, totaling $218 million or $0.40 per diluted share, primarily for costs associated with the Company's planned separation, as well as business development initiatives and intangible asset amortization. These charges were partially offset by a benefit related to a legal settlement.
如 Bob 所提,第二季調整後每股稀釋盈餘為 1.00 美元,優於我們先前發布的每股 0.92 至 0.96 美元的指引區間。依 GAAP 計算之每股稀釋盈餘為 0.60 美元,其中包含稅後特殊項目淨額合計 2.18 億美元(或每股稀釋 0.40 美元),主要為與公司規劃分拆相關的成本,以及業務發展計畫與無形資產攤銷。上述費用部分由一項與法律和解相關的利益所抵銷。
Now let me briefly walk you through the P&L by line item, before turning to the financial outlook for the third quarter and second half of 2015. Starting with sales, worldwide revenues of approximately $3.9 billion, declined 6% on a reported basis. On a constant currency basis, sales increased 3%, which compares favorably to our guidance for the quarter of approximately 1%. Excluding the impact of increased competition for US cyclophosphamide, Baxter sales advanced 4% globally.
在談到 2015 年第三季與下半年財務展望之前,我先依損益表各項目簡要帶各位看一遍。先從營收開始:全球營收約 39 億美元,按報告基礎下降 6%。以固定匯率計算,銷售成長 3%,優於我們對本季約 1% 的指引。若排除美國 cyclophosphamide(環磷醯胺)競爭加劇的影響,Baxter 全球銷售成長 4%。
Medical product sales were in line with our expectations, while strong growth across the BioScience portfolio contributed to the over-achievement. Sales in the US increased 1%, or 5% after adjusting for cyclophosphamide. International sales on a constant currency basis increased 4%.
醫療產品銷售符合我們的預期,而 BioScience 產品組合的強勁成長促成了超越目標的表現。美國銷售成長 1%;若就 cyclophosphamide 進行調整後則成長 5%。國際銷售以固定匯率計算成長 4%。
In terms of individual business performance, within Medical Products, global sales of approximately $2.5 billion declined 9%, and on a constant currency basis, sales were comparable to the prior-year period. Adjusting both periods for the impact of US cyclophosphamide, Medical Products sales rose 3% on a constant currency basis.
就各事業表現而言,在醫療產品部門內,全球銷售約 25 億美元,按報告基礎下降 9%;以固定匯率計算,銷售與去年同期大致持平。若將兩期皆就美國 cyclophosphamide 的影響進行調整,醫療產品銷售以固定匯率計算成長 3%。
Within the product categories, renal sales totaled $949 million, reflecting a decline of 9% on a reported basis. Excluding the impact of foreign currency, sales increased 3%. Performance in the quarter was driven by mid to high single-digit growth in our peritoneal dialysis business, and double-digit growth in the acute business. This growth was offset by lower sales in our chronic hemodialysis business, resulting from our previously mentioned decision to forego certain lower margin sales opportunities, as well as the impact from increased austerity measures in Western Europe.
在產品類別方面,腎臟相關銷售合計 9.49 億美元,按報告基礎下降 9%。若排除外幣影響,銷售成長 3%。本季表現主要受腹膜透析業務中至高個位數成長,以及急性業務雙位數成長所帶動。然而,慢性血液透析業務銷售下滑抵銷了上述成長,原因包括我們先前提及決定放棄部分較低毛利的銷售機會,以及西歐加強緊縮措施所帶來的影響。
Within the fluid system franchise, sales of $518 million declined 3%, and on a constant currency basis, sales advanced 3%. Performance was driven by the relaunch of the SIGMA Spectrum pump in the US during the quarter, and strong demand and favorable pricing for IV fluids. Sales in the integrated pharmacy solutions franchise totaled $548 million, and declined 16%. On a constant currency basis, sales declined 8%, as strength in our hospital pharmacy compounding service business, was offset by lower cyclophosphamide sales in the US.
在輸液系統(fluid system)產品線方面,銷售為 5.18 億美元,下降 3%;以固定匯率計算,銷售成長 3%。表現主要受本季在美國重新上市 SIGMA Spectrum 幫浦所帶動,以及 IV 輸液的強勁需求與有利定價。整合式藥局解決方案(integrated pharmacy solutions)產品線銷售合計 5.48 億美元,下降 16%。以固定匯率計算,銷售下降 8%;其中醫院藥局調配服務業務的強勁表現,被美國 cyclophosphamide 銷售下滑所抵銷。
Excluding this impact, sales in the category advanced 1%. This growth was somewhat dampened given a tough year-over-year comparison, as growth in the second quarter of 2014 was the highest quarterly growth for the year, as product availability improved for certain nutritional products that had previously been supply constrained.
若排除此影響,該類別銷售成長 1%。由於同比基期較高,該成長略受抑制;2014 年第二季為當年季度成長最高的一季,原因是先前供應受限的部分營養產品供貨狀況改善。
Revenues in surgical care, which includes our inhaled anesthetics and biosurgery products were $333 million in the quarter and declined 4%. On a constant currency basis, sales rose 4% driven by strong performance globally in the anesthesia business, and solid growth of our core surgical sealants and hemostasis products, including our market-leading FLOSEAL hemostatic matrix. This performance was partially offset by lower sales of select non-core biosurgery products.
外科照護(surgical care)營收(包含我們的吸入式麻醉劑與生物外科產品)本季為 3.33 億美元,下降 4%。以固定匯率計算,銷售成長 4%,主要由麻醉業務在全球的強勁表現,以及核心外科封合劑與止血產品的穩健成長所帶動,其中包括我們市場領先的 FLOSEAL 止血基質。上述表現部分被部分非核心生物外科產品銷售下滑所抵銷。
Finally, sales in the biopharma solutions and the other category, which is our pharma partnering business, totaled $116 million, declining 6% on a reported basis. Sales increased 2% on a constant currency basis, driven by increased international demand from our contract manufacturing partners.
最後,生物製藥解決方案(biopharma solutions)及其他類別(即我們的製藥合作夥伴業務)銷售合計 1.16 億美元,按報告基礎下降 6%。以固定匯率計算,銷售成長 2%,主要由我們委託製造合作夥伴帶動的國際需求增加所驅動。
Global BioScience sales totaled approximately $1.4 billion in the quarter, and declined 2% on a reported basis. On a constant currency basis, BioScience sales advanced 7%. Additional details on the BioScience performance in the quarter will be available on the Baxalta earnings conference call tomorrow morning.
本季全球 BioScience 銷售合計約 14 億美元,按報告基礎下降 2%。以固定匯率計算,BioScience 銷售成長 7%。關於本季 BioScience 表現的更多細節,將於明天上午 Baxalta 的盈餘電話會議中提供。
Turning to the rest of the P&L, gross margin in the quarter was 50.7%, compared to 50.3% last year. Positive mix, select pricing improvements, and foreign currency hedge gains more than offset the impact from increased generic competition for cyclophosphamide, and incremental manufacturing investments made in the quarter.
接著看損益表其餘項目:本季毛利率為 50.7%,去年為 50.3%。有利的產品組合、部分定價改善,以及外匯避險收益,已足以抵銷 cyclophosphamide 面臨學名藥競爭加劇的影響,以及本季新增的製造投資。
SG&A totaled $951 million, and was comparable to prior-year levels. On a constant currency basis, SG&A increased high single-digits. Growth in the quarter reflect continued investments in promotional and market activities to support new product launches in BioScience, certain costs incurred to establish the regional commercial organizations for Baxalta, and adjustments to bad debt reserves in emerging markets.
SG&A(銷售、一般及行政費用)合計 9.51 億美元,與去年同期水準相當。以固定匯率計算,SG&A 增加高個位數百分比。本季成長反映我們持續投入推廣與市場活動以支持 BioScience 新產品上市、為 Baxalta 建立區域商業組織所產生的部分成本,以及新興市場呆帳準備的調整。
R&D spending in the quarter of $292 million increased 1%. On a constant currency basis, R&D advanced mid teens, and was driven primarily by increased investments in the BioScience business. Interest expense was $30 million in the second quarter, compared to $42 million last year, as we benefited from a favorable rate and debt mix, and higher capitalized interest.
本季研發(R&D)支出為 2.92 億美元,增加 1%。以固定匯率計算,研發支出成長約十幾個百分點,主要由 BioScience 業務投資增加所帶動。第二季利息費用為 3,000 萬美元,去年為 4,200 萬美元;我們受惠於有利的利率與負債組合,以及較高的資本化利息。
Our second-quarter ending debt balance included approximately $5 billion of debt issued by Baxalta in June, which upon the spin has moved to their balance sheet, as well as the retirement of $1.1 billion of commercial paper. Subsequent to the second-quarter, we successfully tendered for $2.7 billion of outstanding bonds. Both the commercial paper reduction and bond tenders were paid down with proceeds from the $4 billion cash dividend that Baxter received from Baxalta in June.
我們第二季期末的債務餘額包含約50億美元,為Baxalta於6月發行之債務;該等債務在分拆後已移轉至其資產負債表,另亦包含償還11億美元商業本票。第二季之後,我們成功以要約收購方式買回27億美元未償還債券。商業本票的減少與債券要約收購所需資金,均以Baxter於6月自Baxalta收到的40億美元現金股利之款項支付。
Other income totaled $[15] million, and included planned gains related to sale of select equity investments. The tax rate of 23.2% for the quarter was slightly above expectations, driven by the one-time impact associated with completing select tax audits, primarily outside the United States. And as previously mentioned, adjusted earnings of $1.00 per diluted share exceeded our guidance range.
其他收入合計為1,500萬美元,並包含出售部分股權投資所帶來的計畫性收益。本季稅率為23.2%,略高於預期,主要係因完成部分稅務稽核所產生的一次性影響,且多發生於美國以外地區。此外,如先前所提,調整後每股稀釋盈餘1.00美元高於我們的指引區間。
Let me conclude my comments this morning, by providing an update on our full year sales guidance and outlook, for both the third quarter and second half of the year. But before I do that, many of you have inquired about restated historical quarterly income statements. We do plan to post adjusted non-GAAP financial statements to our website prior to our third-quarter earnings call to provide investors with historical baseline financials for new Baxter. This timing allows for the completion of the final carve-out process, associated discontinued operations presentation of the BioScience business, as well as the confirmation of the baseline run rate associated with the transition of services agreements we have set up with Baxalta, for which billing will commence in the third quarter.
今天上午我最後做個總結,將就我們全年銷售指引與展望提供更新,涵蓋第三季以及下半年。但在此之前,許多人詢問過重述後的歷史季度損益表。我們計畫在第三季財報電話會議之前,於網站上公布調整後的非GAAP財務報表,為投資人提供「新Baxter」的歷史基準財務資訊。此時間安排可讓與BioScience業務之停業部門表達相關的最終分拆(carve-out)流程完成,同時也能確認我們與Baxalta所建立之過渡服務協議(TSA)相關的基準運行費率;該等服務將自第三季開始計費。
Now, turning to our guidance, and starting with sales, on a constant currency basis, we continue to expect sales for the full year 2015 for new Baxter to be comparable to 2014, primarily due to the impact of generic cyclophosphamide. Adjusting both periods for the cyclophosphamide impact, underlying growth is approximately 3%.
接著談指引,先從銷售開始:以固定匯率基礎計算,我們仍預期2015年「新Baxter」全年銷售額將與2014年大致相當,主要係受學名藥cyclophosphamide的影響。若將兩期皆排除cyclophosphamide影響後調整,基礎成長約為3%。
By franchise, we continue to expect renal sales to increase approximately 3%, and surgical care sales to advance 4% to 5%. For fluid systems, we expect sales growth of approximately 3%. We now expect sales in the integrated pharmacy solutions franchise to decline mid single-digits. As you know, this category includes cyclophosphamide. For 2015, we now estimate US cyclophosphamide sales of $190 million to $200 million.
按事業群別來看,我們仍預期腎臟照護銷售成長約3%,外科照護銷售成長4%至5%。在輸液系統方面,我們預期銷售成長約3%。我們目前預期整合式藥局解決方案(integrated pharmacy solutions)事業群的銷售將下滑中個位數百分比。如各位所知,此類別包含cyclophosphamide。就2015年而言,我們目前估計美國cyclophosphamide銷售額為1.90億至2.00億美元。
This is an increase from our previous guidance, and reflects a benefit of approximately $20 million in the second quarter, and an incremental $20 million to $30 million benefit in the second half of the year, relative to our original guidance. While we continue to expect additional competitors to enter the market, the timing of these entries remains uncertain.
此一數字較我們先前指引上調,反映第二季約2,000萬美元的利多,以及相較於原始指引,下半年額外2,000萬至3,000萬美元的增量利多。雖然我們仍預期會有更多競爭者進入市場,但其進入時點仍不確定。
Growth for the category, after adjusting for cyclophosphamide is expected to increase mid single-digits. And finally, we expect the other category, which includes our biopharma solutions franchise to decline approximately 10%, as a major customer elects to self-manufacture products that were previously contract manufactured by Baxter.
在排除cyclophosphamide影響後,該類別的成長預期將提升至中個位數百分比。最後,我們預期「其他」類別(包含我們的生物製藥解決方案事業群)將下滑約10%,原因是一位主要客戶選擇自行生產先前由Baxter代工生產的產品。
Moving to the second half of 2015, our outlook remains consistent with the guidance we provided at our Investor conference in May. We expect second-half sales growth excluding the impact of foreign currency to be comparable to the prior year. And after adjusting for US cyclophosphamide, to increase approximately 3%. At current foreign exchange rates, we expect reported sales to decline approximately 9%.
談到2015年下半年,我們的展望仍與5月投資人會議所提供的指引一致。我們預期下半年在排除外幣影響後的銷售成長將與去年同期大致相當。而在排除美國cyclophosphamide影響後,將成長約3%。以目前匯率計算,我們預期報告銷售額將下滑約9%。
We anticipate the gross margin for new Baxter to be approximately 42%, and we continue to expect an operating margin of approximately 9%. As previously mentioned, the 9% initial operating margin reflects the impact of stranded costs and incremental pension expenses following the spin-off of Baxalta. It also incorporates investments we've made to enhance our manufacturing and quality systems.
我們預期「新Baxter」毛利率約為42%,並仍預期營業利益率約為9%。如先前所述,9%的初始營業利益率反映Baxalta分拆後的閒置成本(stranded costs)與額外退休金費用之影響。其中亦包含我們為強化製造與品質系統所做的投資。
For the second half, we expect interest expense to total approximately $70 million as the benefit of our reduced debt levels is more than offset by lower levels of capitalized interest. We expect other income of approximately $15 million, reflecting a benefit from the sale of select equity investments in the back half of the year.
就下半年而言,我們預期利息費用合計約7,000萬美元,因債務水位降低所帶來的效益,將被資本化利息水準下降所抵銷且有餘。我們預期其他收入約1,500萬美元,反映下半年出售部分股權投資所帶來的收益。
Given the geographic mix of our earnings for new Baxter, we expect a tax rate of approximately 20%, and for the balance of the year, we expect an average share count of approximately 550 million shares. As stated in our press release, we expect adjusted earnings excluding special items of $0.58 to $0.62 per diluted share.
考量「新Baxter」獲利的地理分布,我們預期稅率約為20%;且在今年剩餘期間,我們預期平均流通股數約為5.50億股。如我們新聞稿所述,我們預期排除特殊項目的調整後每股稀釋盈餘為0.58至0.62美元。
Specific to the third-quarter, we expect sales growth excluding the impact of foreign currency to be comparable to the prior-year, and after adjusting for cyclophosphamide to increase approximately 3%. At current foreign exchange rates, we expect reported sales to decline approximately 9%, and we expect earnings from continuing operations excluding special items of $0.29 to $0.31 per diluted share.
就第三季而言,我們預期在排除外幣影響後的銷售成長將與去年同期大致相當;在排除cyclophosphamide影響後,將成長約3%。以目前匯率計算,我們預期報告銷售額將下滑約9%;並預期排除特殊項目的持續營業每股稀釋盈餘為0.29至0.31美元。
Before we open up the call for Q&A, I'd now like to turn the call back over to Bob for some closing comments.
在我們開放問答之前,我現在想把電話交回給Bob,請他做一些結語。
- Chairman & CEO
- Chairman & CEO
Thanks, Jay.
謝謝,Jay。
As part of our roadshow efforts, following the May Investor conference, we had the opportunity to meet with a significant number of both current, and also potential investors. Given that this, today is really the first public forum that we've had since investor conference, I want to take just a moment to address, and expand upon three key topics, that emerged during many of the meetings.
作為我們路演工作的一部分,在5月投資人會議之後,我們有機會與相當多的現有投資人以及潛在投資人會面。鑑於今天確實是自投資人會議以來我們首次的公開場合,我想花一點時間回應並延伸說明在多場會議中浮現的三個關鍵主題。
The first topic relates to our margin profile. The second relates to our plans for capital allocation, and the last topic centers on management succession. So starting with our margin profile, I can tell you, the confidence that we have in the margin expansion targets we provided in May, has only been enhanced in the subsequent weeks. Momentum is building across the organization, and as some of our recent highlights suggest, we are already making progress on a number of our margin improvement initiatives.
第一個主題與我們的利潤率概況相關。第二個主題與我們的資本配置計畫相關,而最後一個主題聚焦於管理階層接班。先從利潤率概況談起,我可以告訴各位,我們對於5月所提出的利潤率擴張目標之信心,在接下來幾週只增不減。整個組織的動能正在累積;正如我們近期的一些亮點所示,我們已在多項利潤率改善計畫上取得進展。
Enhancing profitability is the top priority for new Baxter. And while our short-term profitability is impacted by certain discrete factors, we know what these are, and we'll be addressing them, along with our broader cost structure in the months ahead. The spin-off of Baxalta has provided us an opportunity to clearly evaluate our entire cost structure, and we're committed to aggressively addressing our cost position to ensure that it's aligned with our new business profile.
提升獲利能力是「新Baxter」的首要任務。雖然短期獲利受到某些特定因素影響,但我們清楚這些因素是什麼,並將在未來數月與更廣泛的成本結構一併加以處理。Baxalta的分拆讓我們有機會清楚檢視整體成本結構;我們承諾將積極處理成本定位,以確保其與我們新的業務樣貌相匹配。
We have demonstrated that we can achieve these targets, as we have been successful in executing against the cost reduction initiatives identified as part of the Gambro acquisition, and as mentioned are on pace to achieve our $300 million target by 2017. And to be clear, the margin targets that we presented in May are not an end state. Both Jay and I emphasized in our prepared comments at the Investor conference, that we expect margin expansion to continue well beyond 2020. As we progress, we will be continue to look for additional actions to not only accelerate profitably, but drive overall margin improvement beyond the targets identified.
我們已證明能達成這些目標,因為我們成功執行了在Gambro併購案中所辨識的成本削減計畫;如前所述,我們正按進度在2017年前達成3億美元的目標。需要說明的是,我們在5月提出的利潤率目標並非終點狀態。我與Jay在投資人會議的事先準備發言中都強調,我們預期利潤率擴張將在2020年之後仍持續推進。隨著我們持續推進,我們也將持續尋找更多行動,不僅加速獲利能力提升,也推動整體利潤率改善超越既定目標。
Turning to capital allocation, and in particular our use of the retained Baxalta equity stake, the decision to retain the stake affords us the opportunity to restructure our balance sheet, in a highly tax efficient manner. As we've shared previously, we intend to use the proceeds of the stake to further reduce debt, repurchase Baxter shares, and to make a contribution to the domestic pension plan pending inventory approval. Over the next 18 months, we'll leverage a combination of these activities to arrive at an optimal mix, that maximizes the value to Baxter and our shareholders, while minimizing the fees and other execution costs resulting from these activities. By reducing debt, we will create capacity for additional borrowing as appropriate to pursue organic and inorganic growth opportunities, while remaining within our targeted leverage ratios.
談到資本配置,特別是我們如何運用所保留的 Baxalta 股權持股,保留該持股的決定讓我們有機會以高度稅務效率的方式重整資產負債表。如同我們先前分享的,我們打算運用該持股的處分所得進一步降低負債、回購 Baxter 股票,並在等待盤點核准的前提下,對國內退休金計畫進行提撥。在未來 18 個月,我們將結合這些活動以達到最佳組合,在將對 Baxter 及股東的價值最大化的同時,把因這些活動所產生的費用及其他執行成本降到最低。透過降低負債,我們將在適當情況下創造額外借款的能力,以追求有機與非有機的成長機會,同時維持在我們目標的槓桿比率範圍內。
As you may have seen this afternoon, we declared our first dividend as a standalone Company. The payout ratio is in line with the target that we shared in May of approximately 35% of adjusted net income, and places us at the high end of our peer set. Going forward, we expect to grow our dividend distribution commensurate with earnings growth, and we remain committed to returning meaningful value to shareholders through dividends and share repurchases.
如同各位今天下午可能已經看到的,我們宣布了作為獨立公司以來的首次股利。配發率符合我們在 5 月分享的目標,即約為調整後淨利的 35%,並使我們位於同業比較中的高端。展望未來,我們預期將隨著盈餘成長相應提高股利配發,同時我們仍致力於透過股利與股票回購,為股東帶來具意義的回報。
Regarding M&A, while it's not included in our initial financial projections going forward, we do expect M&A to be a key component of our strategy to accelerate profitable growth. In the near-term, our M&A activities will be somewhat constrained, by both organizational and financial capacity. Over the next 12 months, however, as we enhance our balance sheet, and progress on our post-spin margin improvement initiatives, we'll have significant flexibility to take full advantage of opportunities that are aligned with our business model, and augment our channel strength, and geographic presence.
關於併購(M&A),雖然我們的初始財務預測並未納入未來的併購,但我們確實預期併購將是我們加速獲利成長策略的關鍵組成。短期內,我們的併購活動將在組織與財務能力兩方面受到一定限制。然而在未來 12 個月,隨著我們強化資產負債表,並推進分拆後的毛利率改善計畫,我們將具備相當大的彈性,充分把握與我們商業模式一致、並能強化通路優勢與地理布局的機會。
The last topic I wanted to address this afternoon and expand upon, relates to the subject of succession planning. Given my tenure as CEO, which is now well over 11 years and my age, this was a very natural question that arose in most of the roadshow meetings. When I came forward to the Board over a year ago to recommend that we consider the spin-off of BioScience, the Board discussed succession planning, and concluded that an undertaking of this magnitude would be enhanced by my continued involvement throughout, to maintain stability within the organization, ensure that the timetable of the spin-off and all associated activities were achieved, and set the stage in the best possible way for both companies to be successful.
今天下午我想談的最後一個主題並進一步說明的,是接班規劃。鑑於我擔任執行長的任期如今已超過 11 年,以及我的年齡,這在多數路演會議中自然成為大家提出的問題。一年多前,當我向董事會提出建議、請董事會考慮分拆 BioScience 時,董事會也討論了接班規劃,並認為如此規模的計畫若由我在整個過程中持續參與將更有助益,以維持組織穩定、確保分拆時程及所有相關活動如期完成,並以最佳方式為兩家公司成功奠定基礎。
At that time, I committed to the Board that I would agree to serve as CEO of new Baxter, long enough to ensure that our goals were clearly defined, that the entire organization was aligned with what we needed to accomplish, and that our progress toward our goals and our confidence in obtaining them, if not exceeding those goals, was evident. While the Board naturally is always working to ensure a plan of succession, with the spin-off successfully completed, the Board is again actively taking up the subject of my succession.
當時我向董事會承諾,我願意擔任新 Baxter 的執行長,直到我們的目標被清楚界定、整個組織與我們需要完成的事項保持一致,且我們朝目標前進的進展與達成目標(甚至超越目標)的信心已清楚可見。董事會本來就會持續確保接班計畫的存在;如今分拆已成功完成,董事會也再次積極著手處理我的接班議題。
And as part of that process, has formed a working group of the Board to manage the search process, and has retained a search firm to assist in this regard. The Board knows that I am available to support in the succession process in every way, and I am willing to serve in whatever capacity the Board feels will provide value. While a specific timetable has not been established, we did want to take advantage of this opportunity to update you on the topic. And, of course, we'll share information as appropriate going forward.
作為該流程的一部分,董事會已成立董事會工作小組來管理遴選流程,並聘請獵才公司協助此事。董事會知道我願意以各種方式支持接班流程,我也願意以董事會認為能帶來價值的任何角色繼續服務。雖然尚未訂定具體時程,但我們也希望把握這個機會向各位更新此一主題。當然,未來我們也會在適當時機分享相關資訊。
So in closing, this is truly a new day at Baxter. The road ahead offers significant opportunities, and we have the strategies in place to leverage these opportunities, to deliver enhanced value for all of our stakeholders. The recent spin-off creates the potential for us to have an even greater impact on the lives of our patients, as we accelerate performance globally.
最後總結,對 Baxter 而言,這確實是嶄新的一天。前方道路充滿重大機會,而我們已具備相應策略來把握這些機會,為所有利害關係人創造更高的價值。近期的分拆讓我們在全球加速提升績效之際,有潛力對病患的生活產生更大的影響。
We are already making it happen, along the key trajectories that I've outlined here. Yet through it all, we're staying true to the same fundamentals, that made us a recognized and trusted global market leader for over 80 years, innovation, quality, efficiency, market access, and improved clinical outcomes for patients worldwide.
我們已經在我於此概述的關鍵軌跡上付諸實行。然而在整個過程中,我們仍堅守同樣的基本原則——正是這些原則讓我們在 80 多年來成為備受認可與信賴的全球市場領導者:創新、品質、效率、市場准入,以及為全球病患帶來更佳的臨床結果。
So with that, I think we can now open up the call to Q&A.
那麼,接下來我想我們可以開放進入問答。
Operator
Operator
(Operator instructions)
(接線員指示)
I would like to remind participants that this call is being recorded, and a digital replay will be available on Baxter International website for 30 days at www.baxter.com. Our first question comes from Bob Hopkins with Bank of America Merrill Lynch, your line is open.
提醒各位與會者,本次電話會議將被錄音,並將在 Baxter International 網站提供 30 天的數位重播,網址為 www.baxter.com。我們的第一個問題來自美國銀行美林(Bank of America Merrill Lynch)的 Bob Hopkins,您的線路已開通。
- Analyst
- Analyst
Thank you. Can you hear me okay?
謝謝。你們聽得到我嗎?
- Chairman & CEO
- Chairman & CEO
We can, Bob, go ahead.
聽得到,Bob,請說。
- Analyst
- Analyst
Great, thanks. So I just wanted to take the opportunity, Bob, to follow up on your comment about succession, and your comment about you want to wait until progress is evident. Is it reasonable to assume that by early 2016, we're going to know what kind of progress, will the progress be evident? I'm just trying to put some time frames around on your commentary around succession.
很好,謝謝。我想把握這個機會,Bob,針對你關於接班的評論,以及你提到想等到進展明顯再說,追問一下。我們是否可以合理地假設,到 2016 年初,我們就會知道進展到什麼程度、進展是否會變得明顯?我只是想為你關於接班的評論加上一些時間框架。
- Chairman & CEO
- Chairman & CEO
Yes, I appreciate the follow-up question, Bob. Again, I don't want to be specific in terms of dates. The reason I did mention what I did, is it's fair to characterize this is a -- what I would call a front burner issue with the Board. I mean, the fact of the matter is, our Board has had in place, through to the governance committee, and established a succession plan, a process for a long time. In fact, just to provide a little color for everyone, we had discussions on this, going back over the last few years. But clearly, as we approached the spin-off, we kind of took the notion of succession, and set it up on the shelf a little bit. I will say the decision to spin-off BioScience, clearly wasn't a result of any succession planning. But the reality is, as a result of the spin-off, it did answer the succession question for that big piece of the business. But it also allows the Board to go forward now, and evaluate succession in the context of a medical products, medical device Company, which in terms of experience and so on is a much more -- can be a much more focused search, I think.
是的,Bob,我很感謝這個追問。再次強調,我不想在日期上說得太具體。我之所以提到那些,是因為可以公平地說,這是董事會——我會稱之為——目前的優先要務。事實上,我們的董事會透過治理委員會,長期以來就已建立接班計畫與流程。其實,為了讓大家更了解一些背景,我們在過去幾年就已經討論過這件事。但很明顯地,當我們接近分拆時,我們某種程度上把接班這個概念先暫時擱置。我要說的是,分拆 BioScience 的決定,顯然不是任何接班規劃的結果。但現實是,分拆之後,確實也為那一大塊業務解答了接班問題。同時也讓董事會現在能夠在一家醫療產品、醫療器材公司的脈絡下推進並評估接班;就經驗等面向而言,我認為這會是一個更——也可能更聚焦的搜尋。
So, now given the fact that the spin has taken place, recognizing the progress and the momentum that's building at new Baxter, as I said, this has now become a new priority. And as I said in my prepared comments, with that the Board has formed a working group to manage the process, retained a search firm. I don't want to get into all the specifics of that, including timing, other than to say, I wouldn't have raised it in this sense, if now, that the spin has been completed. We've got renewed enthusiasm and energy and focus and alignment behind what we want to do at new Bax. And now is appropriate for the Board to reengage on this, and that's why I wanted to comment on this, this afternoon.
因此,既然分拆已經完成,也認知到新 Baxter 正在累積的進展與動能,如我所說,這現在已成為新的優先事項。而且如我在事先準備的發言中提到的,董事會已成立工作小組來管理流程,並聘請獵才公司。我不想深入所有細節,包括時程在內;我只能說,如果不是因為分拆已完成,我不會以這種方式提出這個議題。我們對新 Bax 想做的事情背後,已重新凝聚熱情、能量、專注與一致性。現在正是董事會重新投入此事的適當時機,這也是我今天下午想對此作出評論的原因。
- Analyst
- Analyst
Great. That's very helpful. So I think what I'm hearing from you -- it just doesn't sound unreasonable that something could happen in 2016? Just kind of hearing, the things that you mentioned.
很好。這非常有幫助。所以我想我從你這裡聽到的是——聽起來並不不合理,2016 年可能會有些事情發生?只是根據你提到的那些內容來理解。
- Chairman & CEO
- Chairman & CEO
No, that's not unreasonable at all.
不,這一點也不不合理。
- Analyst
- Analyst
Okay.
好的。
- Chairman & CEO
- Chairman & CEO
The fact of the matter is, we retained a search firm, shortly after the spin. We didn't do before then, because there's no secrets in the world. Stability in this organization is important, and we intentionally as I said, kind of put that on the shelf until the spin was completed. But shortly thereafter we formalized it -- and particularly with our employees, I always try to be forthright and transparent in communications. And it's another reason why I wanted to communicate it today, so they have some expectation in that regard.
事實上,我們在分拆後不久就聘請了一家獵才/搜尋公司。我們在那之前沒有做,因為世界上沒有秘密可言。這個組織的穩定性很重要,而正如我所說,我們刻意先把這件事擱置,直到分拆完成。但在那之後不久我們就把它正式化——尤其是對我們的員工,我一向努力在溝通上坦率且透明。這也是我今天想要溝通的另一個原因,讓他們在這方面有一些預期。
- Analyst
- Analyst
Great. And then, just one really quick one for Jay. Given your back half guidance, could you give us a sense as to the revenue contribution from cyclo in the back half? And then, the total debt of Baxter in the back half that drives the interest expense number you mentioned? Thank you.
很好。接著,還有一個很快的問題想問 Jay。依照你們對下半年的指引,能否讓我們了解 cyclo 在下半年的營收貢獻大概是多少?另外,下半年 Baxter 的總負債是多少,以致於推動你提到的利息費用數字?謝謝。
- CFO
- CFO
Yes, certainly. As far as cyclo in the second half of the year, we currently expect approximately $70 million in the second half of the year, which is a slight increase over our prior guidance. And then, as far as the new Baxter debt balance in the second half of the year, the -- we completed the debt tender successfully as I commented on in my prepared remarks. At this stage, we are not reflecting any utilization of the retained stake beyond that. But overall from a debt standpoint post-spin, we're anticipating approximately $6.3 billion in debt, which reflects the benefit of utilizing the cash from the cash dividend from Baxalta to retire certain debt and commercial paper. That's the current expectation.
好的,當然可以。就今年下半年的 cyclo 而言,我們目前預期下半年約為 7,000 萬美元,較先前指引略有上調。至於下半年新的 Baxter 負債餘額——正如我在事先準備的發言中提到的,我們已成功完成債務要約收購(debt tender)。在此階段,除了上述之外,我們尚未反映對保留持股(retained stake)的任何動用。但整體而言,從分拆後的負債角度來看,我們預期約有 63 億美元的負債,這反映了運用 Baxalta 現金股利所帶來的現金來償還部分債務與商業本票的效益。這是目前的預期。
- Analyst
- Analyst
Great. Thank you very much.
很好。非常感謝。
Operator
Operator
Our next question comes from Matt Taylor with Barclays, your line is open.
下一個問題來自 Barclays 的 Matt Taylor,您的線路已開通。
- Analyst
- Analyst
Hi, thanks for taking the question. I wanted to ask a question, I guess, about the overall guidance, and any thoughts you have on margins? I mean, specifically on the guidance you gave us second half number, can you put that in context in terms of what that implies for earnings power for the year? And then, also talk about some of the levers that you have year over year, and whether there's been any change to your thoughts on margin expectations for next year?
嗨,謝謝讓我提問。我想問一個問題,我想是關於整體指引,以及你們對利潤率的看法?我的意思是,特別是你們給的下半年指引數字,能否從脈絡上說明這對全年獲利能力意味著什麼?另外,也請談談你們逐年(year over year)有哪些槓桿,以及你們對明年利潤率預期的想法是否有任何改變?
- CFO
- CFO
Yes, I would say our margin expectations for the second half of the year, first, let's start with that, are very consistent with what we shared in the investor conference. So the 9% operating margin reflects the -- our expectation around the start point, and there are a number of factors that are impacting that 9%. As we move forward, we are increasingly confident in our ability to achieve our long-term margin projections. Having said that, I don't think it's appropriate at this stage to modify our target for next year. As you know, we expect 100 basis points of improvement relative to the second half, so 10% margin for next year. And that would include approximately 100 basis points of negative drag from cyclo. So really the organic improvement would be approximately 200 basis points relative to the second half of this year.
是的,我會說我們對下半年利潤率的預期——先從這點開始——與我們在投資人會議上分享的內容非常一致。因此,9% 的營業利潤率反映了——我們對起始水準的預期,而有多項因素正在影響這個 9%。隨著我們往前推進,我們對達成長期利潤率預測的能力愈來愈有信心。話雖如此,我認為在此階段不適合調整我們對明年的目標。如各位所知,我們預期相較於下半年改善 100 個基點,因此明年利潤率為 10%。其中將包含約 100 個基點來自 cyclo 的負面拖累。因此,真正的有機改善相較於今年下半年約為 200 個基點。
As it relates to the full-year comparables and the earnings power, given the complexities of a mid year split, we are really not in a position at this stage to comment on new Baxter as a standalone enterprise. We reported Q2 as a consolidated enterprise. We expect later in the year, as we approach the Q3 earnings call, we'll have the ability to (inaudible) Baxalta, not only from a discontinued operations basis but also at that stage, reflect the transition service agreement, and the actual consumption of transition services by Baxalta. We'll start billing for that, those services that we provide next month. So from an overall standpoint, the first half of the year really is a Baxter consolidated view, until we modify that later in the year.
至於全年可比性與獲利能力(earnings power),鑑於年中分拆的複雜性,我們目前確實還無法就新的 Baxter 作為獨立企業發表評論。我們第二季是以合併企業(consolidated enterprise)口徑報告。我們預期在今年稍晚、接近第三季財報電話會議時,我們將有能力(聽不清)Baxalta,不僅以停業單位(discontinued operations)基礎呈現,並且在那個階段反映過渡服務協議(transition service agreement),以及 Baxalta 實際使用過渡服務的情況。我們將從下個月開始就我們提供的那些服務進行計費。因此,從整體角度來看,今年上半年基本上仍是 Baxter 的合併視角,直到我們在今年稍晚進行調整。
- Chairman & CEO
- Chairman & CEO
Matt, this is Bob. Maybe just to add some higher level color. It's really too early subsequent to the investor conference for us to modify, either our outlook for this year or next year. But I think probably, as you gathered from our commentary in our prepared remarks, we increasingly are confident in our ability to achieve what we disclosed to everybody, and what we projected at the investor conference. I think the momentum is building. And just to reiterate our aspiration, if we can do better, we are totally committed to do that, both over the next five years in the LRP, and certainly subsequent to 2020. So, good momentum building. But it's too early in the game, I think, to modify any of our financial projections.
Matt,我是 Bob。也許我補充一些更高層次的說明。在投資人會議之後的這個時間點,對我們來說要調整今年或明年的展望都還太早。但我想,正如你從我們事先準備的發言評論中所感受到的,我們對達成已向各位揭露、並在投資人會議上所預測的目標,信心正持續提升。我認為動能正在累積。再重申一次我們的企圖心:如果我們能做得更好,我們完全承諾會做到——無論是在未來五年的長期計畫(LRP)中,當然也包括 2020 年之後。所以,動能良好、正在建立。但我認為現在還太早去調整任何財務預測。
- Analyst
- Analyst
Okay. Thanks a lot for the color.
好的。謝謝你提供的說明。
- Chairman & CEO
- Chairman & CEO
Sure.
不客氣。
Operator
Operator
Our next question comes from David Roman with Goldman Sachs, your line is open.
下一個問題來自 Goldman Sachs 的 David Roman,您的線路已開通。
- Analyst
- Analyst
Thank you, and good afternoon, everybody. I wanted to just to start with a couple of questions on the business. If you look at very specifically, at the fluid systems franchise, it looks like in the US that that business continues to do a little bit better than what one might expect your end markets to be growing at right now. Could you talk about the key drivers underpinning the strength in the US, and to what extent these type of growth rates are sustainable?
謝謝,各位下午好。我想先從業務方面的幾個問題開始。如果非常具體地看流體系統(fluid systems)事業群,在美國看起來該業務的表現仍比你們終端市場目前的成長速度所暗示的還要好一些。能否談談支撐美國市場強勁表現的關鍵驅動因素,以及這類成長率在多大程度上是可持續的?
- Chairman & CEO
- Chairman & CEO
Well, just maybe a high-level comments, and then I can maybe tee it up for Jay for more specifics. Some of the strength that you're seeing demonstrated is really of result of pricing -- some pricing power, pricing latitude in the US. The underlying volume is, I think pretty consistent with what we been generating. As you know, it's a fairly low growth market on a volume basis. But what you're seeing the strength from is really, in the core solutions business is really pricing. But then, of course, we are starting to pick up momentum more broadly with the relaunch of SIGMA Spectrum. And I will tell you again -- and you know this David, but for the others that are calling in, we projected in the long-range plan to recover 5 of the 10 share point loss within the LRP. And early days with orders we have in hand, and where we expect this year, I would anticipate that we are going to get at least 1 share point of that buyback, before the end of the year. So, that's part of the momentum that's building there, and that's contributing to the strength as well. Jay, I don't know if there are any --
嗯,我先做一些高層次的評論,然後我也許再請 Jay 補充更具體的內容。你所看到的一些強勁表現,主要是定價的結果——在美國有一些定價能力、定價空間。我認為基礎出貨量(volume)與我們一直以來的表現相當一致。如你所知,就量的角度來看,這是一個成長相當低的市場。但你看到的強勁,主要來自核心解決方案業務的定價。當然,隨著 SIGMA Spectrum 的重新上市(relaunch),我們也開始在更廣泛的層面上累積動能。我再說一次——你也知道這點,David,但也讓其他來電者了解——我們在長期計畫中預測,在 LRP 期間要收復 10 個市占點流失中的 5 個。以目前手上的訂單以及我們對今年的預期來看,我預估在年底前,我們至少會回補其中 1 個市占點。因此,這也是那裡正在累積的部分動能,也同樣在促成這股強勁。Jay,我不知道是否還有——
- CFO
- CFO
Nothing to add.
沒有要補充的。
- Chairman & CEO
- Chairman & CEO
Specifics you want to add to that? Those are the key components, David.
你還想補充哪些細節嗎?David,這些就是關鍵組成要素。
- Analyst
- Analyst
Okay, that's helpful. Then maybe just turning to the surgical care franchise. That's a business looks like it is maybe doing a little bit better, but obviously, an area that is fairly intense on that pricing competition side. Do you think this is a business that we can see accelerate on a go forward basis, particularly as there's evidence continues to come through on better US hospital volumes and surgical volumes? Or is this a franchise that is permanantly constrained through a lower single-digit growth rate?
好的,這很有幫助。那麼也許再轉到外科護理(surgical care)事業群。這項業務看起來可能表現稍微好一些,但顯然在價格競爭方面是相當激烈的領域。你認為這項業務未來是否有機會加速成長,特別是在美國醫院量與手術量持續改善的證據不斷出現之際?還是說,這個事業群會長期受限於較低的個位數成長率?
- Chairman & CEO
- Chairman & CEO
There is two different pieces here, and again, I'll ask Jay and Claire and Scott to add commentary as appropriate. For the biosurgery, what we historically we've classified as the biosurgery business. Two different stories, a fairly mature market in the US, and growing with surgical procedures with some additional penetration, and the opportunity for growth longer-term is clearly OUS, and that's the area of additional promotional investment and focus going forward.
這裡有兩個不同的部分,而且同樣地,我會請 Jay、Claire 和 Scott 視情況補充說明。就生物外科而言,也就是我們過去歷來歸類為生物外科業務的部分。這是兩個不同的故事:美國市場相當成熟,隨著外科手術量增加並伴隨一些額外滲透而成長;而長期成長機會顯然在美國以外(OUS),這也是未來我們將加碼推廣投資並聚焦的領域。
The anesthesia business continues to perform quite well, with the adoption of inhalation anesthetic agents in emerging and developing markets continues to grow. As you know, we have the only full-line of inhalation gases, and Suprane continues to perform very well. So the anesthesia business is a little different than the biosurgery business if you will, not constituting our surgical care franchise. But I think realistically, the kind of growth that we project at the investor conference in a range of 4% to 5% at this point, continues to be a prudent expectation. I wouldn't increase expectations beyond that at this stage. Guys, do you want to anything?
麻醉業務持續表現相當不錯,吸入式麻醉劑在新興與發展中市場的採用率仍在成長。如各位所知,我們是唯一提供全系列吸入性麻醉氣體的公司,而 Suprane 也持續表現非常好。因此,若要說的話,麻醉業務與生物外科業務有些不同,並不構成我們的外科照護事業群。但我認為務實來看,我們在投資人會議上所預估的成長區間(目前約 4% 到 5%)仍然是審慎且合理的預期。在這個階段我不會把預期提高到超過這個範圍。各位要補充什麼嗎?
- CFO
- CFO
No, I think that's a good answer.
不,我覺得這個回答很好。
- Chairman & CEO
- Chairman & CEO
Okay.
好的。
- Analyst
- Analyst
Thank you very much.
非常感謝。
Operator
Operator
Our next question comes from the line of David Lewis with Morgan Stanley, your line is open.
下一個問題來自 Morgan Stanley 的 David Lewis,您的線路已開通。
- Analyst
- Analyst
Good afternoon. Just, Jay, a quick question on the Baxalta stake. I know you talked about the balance sheet moves here in the back half of the year. But obviously a lot of what you've talked implies you sell a material portion of Baxalta stake before the end of 2016. So are there any special dynamics underpinning the timing of that sales process, meaning should we expect it to be more immediate post the spin, or closer to the end of 2016? And then, I have a quick follow-up.
午安。Jay,我有個關於 Baxalta 持股的簡短問題。我知道你談到今年下半年在資產負債表方面的動作。但顯然,你談到的很多內容都意味著你們會在 2016 年底前出售 Baxalta 持股中相當重要的一部分。所以,是否有任何特殊因素支撐這個出售流程的時點安排?也就是說,我們應該預期在分拆後不久就更快進行,還是更接近 2016 年底?另外我還有一個簡短的追問。
- CFO
- CFO
Yes, David, if you think about our objectives with the Baxalta stake, it's really to maximize the value of the stake to Baxter. And as part of that, we're going to look to carefully evaluate the different levers that we have, and be opportunistic in terms of timing and amounts in each. And so, I wouldn't say specifically there's a specific time that we are targeting. We probably not going to do anything in the first 60 days, allow the Baxalta stock price to stabilize. And we would probably not wait until we get to close to the 18 month time frame, because as you know there are very significant tax benefits to achieving our objectives within the 18 month time frame.
是的,David,如果你從我們對 Baxalta 持股的目標來看,核心就是要為 Baxter 將這筆持股的價值最大化。作為其中一部分,我們會仔細評估手上不同的槓桿,並在時點與每次的數量上採取機會主義的做法。因此,我不會說我們鎖定某個特定時間點。我們大概不會在前 60 天做任何動作,讓 Baxalta 的股價先穩定下來。而且我們大概也不會等到接近 18 個月的期限,因為如你所知,在 18 個月期限內達成我們的目標,會有非常顯著的稅務效益。
Beyond that, we expect to start certain transactions this year, and then we'll do a number of other transactions next year. But we haven't reflected the benefit in reduced share count or reduced interest expense for late year transactions that we're currently contemplating. The key inputs, as we think about this, with respect to the pension, we're going to carefully evaluate the prevailing interest rate environment, because we don't want to oversize the pension contribution, depending on the size of that liability. We going to carefully evaluate the evolution of the Baxalta stock price. And then, the receptivity to -- what we -- the anticipated receptivity from Baxter debt holders and Baxter shareholders, to the different tactics that we're pursuing. So those are some of the key inputs we're evaluating, as we look at timing and sizing of the different transactions. At this stage, I wouldn't expect one very large transaction, but more multiple transactions.
除此之外,我們預期今年會開始進行某些交易,明年也會進行其他多筆交易。但對於我們目前正在考慮、將在年底較晚時點進行的交易,我們尚未把其帶來的股數減少或利息費用降低的效益反映進去。就我們思考這件事的關鍵輸入而言,關於退休金,我們會仔細評估當前的利率環境,因為我們不希望在負債規模取決於利率變動的情況下,把退休金提撥做得過大。我們也會仔細評估 Baxalta 股價的演變。此外,還會評估 Baxter 債權人與 Baxter 股東對我們所採取不同策略的預期接受度。因此,這些是我們在評估不同交易的時點與規模時所考量的一些關鍵因素。在這個階段,我不預期會有一筆非常大的單一交易,而是會有多筆交易。
- Analyst
- Analyst
Okay, that's very helpful color, Jay. And then, Bob, I just want to come back to renal for a second here. I feel like it's a tale of two cities, where you have great enthusiasm around CRT and some positive secular tailwinds, and you have the more traditional [HD] business, which is perhaps a little sluggish. So what assumptions are you making for price erosion in the traditional HD business, and you talked about some of those in this quarter. How much of this is coming from true austerity? How much is coming from direct decisions you are making about mix, and how much is just coming from the competitors using price as a weapon in the channel? Thanks.
好的,Jay,這些補充非常有幫助。接著 Bob,我想再回到腎臟業務談一下。我覺得這有點像「兩個城市的故事」:一方面大家對 CRT 很有熱情,也有一些正面的長期結構性順風;另一方面較傳統的 [HD] 業務可能有點疲弱。所以你們對傳統 HD 業務的價格侵蝕做了哪些假設?你在本季也提到其中一些。這當中有多少是來自真正的撙節政策?有多少是來自你們在產品組合上的直接決策?又有多少只是競爭對手在通路中把價格當作武器?謝謝。
- Chairman & CEO
- Chairman & CEO
It's probably some of each, so maybe -- and thanks for the question, and I will play it back, and I will ask the team to contribute as appropriate. It's probably the tale of three cities, maybe. One is the acute piece in the hospital, which continues to grow very nicely, double digits and higher margin, and we continue to increase our focus on that. The traditional in-center hemodialysis business which I'll come back to a second. And then, the third leg, of course, is peritoneal dialysis which continues to be an attractive growth vehicle, and also an area that has pricing latitude going forward as well. So the area that I think, you used the word sluggish, is probably a fair way to describe the traditional in-center hemo business. Although I would say that having the full product line, we're seeing that manifests itself in helping us in the PD business as well. So I think increasingly going forward, we have to look at this business in its totality. So, on a constant currency basis, it grew 3% in the third quarter. As you know, we're projecting the long-term growth to be in the 5% to 6% range, and that will be driven over time by capacity expansions later in 2016, with [dialyzer capacity] expansion, and then augmented by PD capacity expansion, largely in Asia subsequent to that. And then, augmenting that, of course, with the new products which we're very excited about.
可能每一項都有一些,所以——也謝謝你的問題。我先把它重述一下,並請團隊視情況補充。這可能更像是「三個城市的故事」。第一個是醫院內的急性端業務,仍持續非常漂亮地成長,達到兩位數且毛利更高,我們也持續加大對這部分的聚焦。第二個是傳統的院內(in-center)血液透析業務,我等一下再回來談。第三個支柱當然是腹膜透析(PD),它仍是具吸引力的成長載體,而且未來在定價上也有一定的彈性空間。所以我認為你用「疲弱」來形容的,可能確實比較符合傳統院內血透業務的狀況。不過我也會說,因為我們擁有完整產品線,我們也看到這點在 PD 業務上同樣帶來助益。因此我認為未來我們必須愈來愈以整體角度來看待這項業務。以固定匯率計算,第三季成長了 3%。如你所知,我們預估長期成長將落在 5% 到 6% 的區間,而這將隨時間推進,主要由 2016 年稍晚的產能擴充所驅動,包括 [透析器產能] 擴充,之後再由主要在亞洲的 PD 產能擴充加以強化。此外,當然還會再加上我們非常期待的新產品。
So let me come back, then to the traditional in-center piece. It's a combination of things. We are being more discerning, relative to the profitability of that business. I think we commented in first quarter about some tenders, that candidly we walked away from, because of the returns. It is a price competitive business, and we have assumed, in answer to your question specifically, price erosion for that segment over the LRP in the very low single-digits. But I think a practical recognition of the continued competitive nature of that.
那我回到傳統院內這一塊。這是多種因素的組合。相較於該業務的獲利性,我們變得更為審慎挑選。我想我們在第一季曾提到一些標案,坦白說我們因為報酬因素而選擇退出。這是一個價格競爭激烈的業務;針對你具體的問題,我們在 LRP(長期規劃)中對該分部假設的價格侵蝕幅度為非常低的個位數。但我認為這是對其持續競爭態勢的務實認知。
And then, there are austerity measures. One of which was recently implemented in France, where as a matter of policy they said, we want to extend the useful life of monitors from 7 years to 10 years. So that obviously has an impact on revenue on monitors, and I would emphasize, our profitability on monitors is at the low end, and whether it's an old monitor or a new monitor, they chew up the same number of dialyzers, and frankly, it reduces our CapEx to some degree as well. So net-net, I'm not sure on the bottom line how significant that is, but it's a contributing factor to the top line. So, I touched on a number of things there. I think I've answered each of your specific questions. I'll stop there. Does that address your questions, David?
另外也確實存在撙節措施。其中一項最近在法國實施:政策上他們表示,希望將監測設備的使用年限從 7 年延長到 10 年。這顯然會影響監測設備的營收;我也要強調,我們在監測設備上的獲利率處於較低端,而且不論是舊監測設備或新監測設備,使用的透析器數量都一樣;坦白說,這也在某種程度上降低了我們的資本支出(CapEx)。因此整體而言,我不確定對最終獲利的影響有多大,但它確實是影響營收的一個因素。所以我剛才提到了幾個面向。我想我已經回答了你每一個具體問題。我先說到這裡。David,這樣有回答到你的問題嗎?
- Analyst
- Analyst
Yes, Bob, very helpful. Thank you.
是的,Bob,非常有幫助。謝謝你。
Operator
Operator
Our next question comes from Mike Weinstein with JPMorgan, your line is open. Your line is open.
我們的下一個問題來自摩根大通(JPMorgan)的 Mike Weinstein,您的線路已開通。您的線路已開通。
- Analyst
- Analyst
Thanks. So Jay, a quick one first. The FX hedges you mentioned on the gross margin line, how much do they contribute in the quarter? And then, Bob, I want to follow-up -- Bob Hopkins discussion with you on succession. So it sounded like a few weeks ago, let's call it, late June, you were talking about the dialogue with the Board being, you need to get the spin and new Baxter if you would, off on the right foot, and you wanted to see that through. But it sounds like now what you're saying is, it's more likely that a new CEO is on board at some point in 2016. Just want to make sure we're hearing that correctly?
謝謝。所以 Jay,先問一個簡短的。你提到毛利率項下的外匯避險,這一季大約貢獻了多少?然後,Bob,我想追問一下——關於 Bob Hopkins 跟你討論的接班安排。聽起來幾週前,我們姑且說是六月下旬,你在談到與董事會的對話時表示,你需要把分拆以及新的 Baxter(如果你願意這麼稱呼)帶上正軌,並且你想把這件事看著完成。但現在聽起來你說的是,更有可能在 2016 年某個時間點會有新任 CEO 到位。我只是想確認我們是否聽得正確?
- Chairman & CEO
- Chairman & CEO
Well, I said it was possible that a new CEO could be on board in 2016. The reality is, I think there has been benefit, and will continue to be benefit by my continued involvement post-spin for a lot of different reasons. But the reality is the progress we're making -- I think the focus and the momentum and the alignment behind what we need to do, is really good. I'm going to be 65 in January. I've been around almost 11.5 years. So inevitably, this has to be dealt with. So I think actually, the stage is set very nicely for the Board now, to do what they have a primary responsibility of doing, is to revisit the issue of succession now that the spin has been successfully executed, and transitioned. And succession has been defined for Baxalta now to focus on the Baxter piece. So I think we can achieve the objective of stability post-spin. I intentionally didn't define a specific date. But I did respond to Bob's question in a fashion that you reiterated, and I think that's fair. So I think it's a good plan, where all objectives can be effectively met. Jay?
嗯,我說的是 2016 年有可能會有新任 CEO 到位。現實是,我認為在分拆之後我持續參與,基於很多不同原因,已經帶來好處,並且會繼續帶來好處。但現實是我們正在取得的進展——我認為我們需要做的事情背後的聚焦、動能與一致性,真的非常好。我一月就 65 歲了。我在這裡將近 11.5 年。所以這件事終究必須處理。因此我認為,現在舞台其實已經為董事會非常好地搭建起來了,去做他們首要責任之一的事情:在分拆成功執行並完成過渡之後,重新檢視接班議題。而且 Baxalta 的接班已經界定清楚,現在可以把焦點放在 Baxter 這一塊。所以我認為我們可以達成分拆後穩定的目標。我刻意沒有定義一個具體日期。但我確實以你剛才重述的方式回覆了 Bob 的問題,我覺得那樣很公平。所以我認為這是一個好計畫,所有目標都能有效達成。Jay?
- CFO
- CFO
Mike, yes, on your gross margin hedge question, we did have the benefit of $25 million of hedges in the second quarter on the gross margin line.
Mike,是的,關於你毛利率避險的問題,我們在第二季於毛利率項下確實受惠於 2,500 萬美元的避險收益。
- Analyst
- Analyst
Wow, okay. And then, maybe just one follow-up, and this is Jay, probably for you. One of the discussions coming out of analyst meeting on new Baxter is the spread, or disconnect if you would, between the net income and free cash flow. I think you guys guided to basically down to about $1.40 in cash earnings, depending on what the share count is next year, and the timing of some of what you do with Baxalta. And that compares to free cash flow of $400 million, which would be about $0.75 to $0.85 And so, can you just talk a little bit about that -- of what disconnect of that spread? And then, how you think about that narrowing if you would, over the next several years? Thanks.
哇,好,了解。然後也許再追問一個,這個應該是給 Jay 的。在新 Baxter 的分析師會議後,有一個討論是淨利與自由現金流之間的差距,或者說脫鉤。我想你們指引大致是,明年現金盈餘大概降到每股約 1.40 美元,取決於明年的股數,以及你們對 Baxalta 的一些動作時點。而這與 4 億美元的自由現金流相比,約相當於每股 0.75 到 0.85 美元。所以你能否談談這個差距——這個利差背後的原因?以及你如何看待未來幾年這個差距逐步收斂?謝謝。
- CFO
- CFO
Great. So the primary driver of the spread between operating income or cash earnings, and free cash flow relates to in the short-term, CapEx. As you know, Mike, our business is capital intensive. A lot of that has to do with the fact that we are in the IV and PD business, and those have a higher capital burn. In addition to that, in the near-term, we've announced a number of important capacity expansion projects that start to benefit sales in 2016. The three major projects that we have ongoing that we'll complete in 2016, we have a China PD expansion, we have a Thai PD expansion, and we have the Opelika dialyzer capacity expansion. All of these are revenue generating, all of these generate positive economics for Baxter, but they do have the impact in the near-term of depressing free cash flow relative to operating income. Over time, as we migrate and improve the operating margin of the business, we will hold CapEx flat, or even as I said in the investor conference, we'll see a decline in CapEx. And so, the relationship between free cash flow and operating income becomes much more normalized.
好的。所以,營業利益或現金盈餘與自由現金流之間差距的主要驅動因素,短期來看與資本支出(CapEx)有關。如你所知,Mike,我們的業務是資本密集型。其中很大一部分原因在於我們從事靜脈輸注(IV)與腹膜透析(PD)業務,而這些業務的資本消耗較高。此外,在短期內,我們已宣布多項重要的產能擴張專案,並將在 2016 年開始對銷售帶來效益。我們目前進行中的三個主要專案,將在 2016 年完成:中國的 PD 擴產、泰國的 PD 擴產,以及 Opelika 的透析器(dialyzer)產能擴張。這些專案都能帶來營收、都能為 Baxter 創造正向經濟效益,但短期內確實會使自由現金流相對於營業利益受到壓抑。隨著時間推進,當我們逐步提升並改善業務的營業利益率時,我們會讓資本支出維持持平,甚至如我在投資人會議所說,資本支出會下降。因此,自由現金流與營業利益之間的關係會變得更為正常化。
Mike, but having said all of this, I want to emphasize that the entire management team is very much focused on free cash flow generation. And while we have a plan on CapEx, we are extremely focused on every single capital project to ensure that those dollars, are dollars that create economic value for the Company. So that's a little background color, and some further information for you.
Mike,不過即便如此,我想強調整個管理團隊都非常專注於自由現金流的創造。雖然我們對資本支出有一套計畫,但我們對每一個資本專案都極度重視,以確保這些資金投入能為公司創造經濟價值。以上提供一些背景說明,以及更多資訊給你參考。
- Analyst
- Analyst
That's good. Thank you, Jay.
很好。謝謝你,Jay。
Operator
Operator
Our next question is from Danielle Antalffy with Leerink Partners, your line is open.
我們的下一個問題來自 Leerink Partners 的 Danielle Antalffy,您的線路已開通。
- Analyst
- Analyst
Hi, good afternoon guys. Thanks so much for taking the question. Bob, just to follow up on a question from earlier, regarding the sales outlook. I mean, this is obviously a very strong sales growth quarter. So I was hoping you could help me better understand -- I guess I should say, very strong, better-than-expected. So I was hoping you could help me better understand, the sort of near to medium term. Actually, let me ask it, medium to longer term headwinds, that makes you think you can't grow faster than the long-term 4% sales growth target that you put out at the Analyst meeting?
嗨,各位下午好。非常感謝讓我提問。Bob,我想延續先前關於銷售展望的問題。這一季顯然是非常強勁的銷售成長。所以我希望你能幫我更好地理解——我想應該說,非常強勁、且優於預期。因此我希望你能幫我更好地理解,短期到中期的情況。其實讓我這樣問:中期到長期有哪些逆風,讓你認為你們無法比分析師會議上提出的長期 4% 銷售成長目標更快成長?
- Chairman & CEO
- Chairman & CEO
Well, actually, thanks for the question, Danielle. We need to pick up the pace a little bit right now, to get to the 4%. We were 3% for the quarter. So we know the primary driver for that, would be with the capacity expansions in renal, both dialyzers and PD capacity, as well as momentum with the SIGMA Spectrum relaunch, and the other new products.
嗯,Danielle,謝謝你的問題。我們現在其實需要把速度再加快一點,才能達到 4%。我們這一季是 3%。所以我們知道主要的驅動因素會來自腎臟業務的產能擴張,包括透析器與 PD 產能,以及 SIGMA Spectrum 重新上市所帶來的動能,還有其他新產品。
To get ahead of ourself, first of all, if you adjust -- if you go back to the 4% CAGR that we talked about over the LRP at the Investor conference, adjusting for cyclophosphamide, that's actually closer to 5%. So that means you're really growing from a current run rate of 3% up to 5%. And the other point that I would reiterate is, is a part of the margin improvement program, and really addressing the product portfolio, we are going to aggressively evaluate certain product categories in certain geographies, which may result in us exiting those product lines in certain geographies, which obviously has a depressing effect on the top line as well.
先別走得太快。首先,如果你調整——如果你回到我們在投資人會議上談到、在長期規劃(LRP)期間的 4% 複合年成長率(CAGR),並把 cyclophosphamide 的影響調整掉,那其實更接近 5%。這表示你實際上是要從目前約 3% 的成長速度提升到 5%。另外我想再重申的一點是,作為毛利率改善計畫的一部分,並且真正去處理產品組合,我們將在特定地區對某些產品類別進行積極評估,這可能導致我們在某些地區退出那些產品線,而這顯然也會對營收(top line)造成壓抑。
So, we do have some momentum implicit in our long-term projections. But we wanted to also reflect the fact, that we are going to be proactively addressing portfolio in a way, that may result through some decreases in revenue. Not unlike the tender -- for the tender position, we took in the first quarter on hemodialysis monitors. So I think overall, it's balanced. I think our long-range sales projection in the LRP is very achievable. Adjusting for cyclophosphamide, I think, it's pretty stable, and fairly predictable. And again, of course, it doesn't reflect anything in there for -- not only M&A obviously, but any further business development as well. So, I think, Danielle, it's a pretty balanced forecast, both for the rest of the year of 2016 and throughout the LRP.
因此,我們在長期預測中確實隱含了一些動能。但我們也希望反映一個事實:我們將以更主動的方式來處理投資組合,而這可能會因為某些營收下滑而產生影響。這點有些類似於第一季在血液透析監測器上,我們針對標案——就標案部位所採取的作法。所以我認為整體而言是平衡的。我認為我們在 LRP 中的長期銷售預測非常可達成。在針對 cyclophosphamide 進行調整後,我認為它相當穩定,也相當可預測。而且再次強調,當然,裡面並未反映任何——不僅是併購(M&A)顯然沒有,任何進一步的業務開發也沒有納入。所以我認為,Danielle,這是一個相當平衡的預測,涵蓋 2016 年剩餘期間以及整個 LRP。
- Analyst
- Analyst
Okay, that's helpful. And then, just to follow up on your comment on business development M&A, given the fact that the Board is actively now searching for your successor, is it fair to assume that nothing major will happen on the business development side until a new CEO is in place? Or are you still actively looking to do things for the rest of your tenure?
好的,這很有幫助。接著,針對你提到業務開發與併購(M&A)的評論,鑑於董事會目前正積極尋找你的接班人,是否可以合理假設,在新任 CEO 就位之前,業務開發方面不會有任何重大動作?還是說,在你任期剩餘時間內,你們仍會積極尋求推動一些事情?
- Chairman & CEO
- Chairman & CEO
We are continuously looking at deals. Our, other then Gambro, our historical MO of doing kind of bolt-on deals and so on, we certainly conceivably can do over the next 12 months. But as a practical matter, we have financial constraints. So the notion of a transformational deal is interesting, and we can talk about it in a hypothetical context. But as a practical matter in the short-term, we don't have the financial wherewithal to do anything in the short-term. And if that's the case, then to speculate one way or the other, telegraph intent ahead of time, doesn't serve -- doesn't seem to serve any stakeholders interest effectively.
我們一直都在持續看案子。我們——除了 Gambro 之外——過去一貫的作法是做一些類似加掛式(bolt-on)的交易等等,未來 12 個月內我們當然也有可能做到。但從實務面來看,我們有財務上的限制。所以,所謂的轉型型交易確實很有意思,我們也可以在假設性的情境下討論。但就短期實務而言,我們沒有足夠的財務能力在短期內做任何事情。如果是這樣,那麼無論往哪個方向去臆測、或提前釋放意圖訊號,都無助於——看起來也無法有效服務任何利害關係人的利益。
The Gambro deal I think, represents the fact that we're willing to think bigger, if the value is there. And whether it's me or a successor, I think there's an open-mindedness to that. But again, right now today, it's not a practical option just due to constraints, right, financial constraints. Not to mention, I would say, organizationally, we're completing the Gambro integration. This Company has been consumed over the last 12 months as a result of the spin-off, which has been the number one priority, and appropriately so. Because I believe we'll look back, and realize that decision will have generated significant value for all stakeholders and all shareholders for both companies. Now that that's done, we refocus our attention on other priorities. But I think a transformational deal in the next say, 12 months or something isn't in the offing, because we don't have the financial latitude to do it.
我認為 Gambro 這筆交易代表了:只要價值在那裡,我們願意把格局想得更大。不論是我或接班人,我認為對此都保持開放的心態。但再次強調,就今天此刻而言,因為限制——也就是財務限制——它並不是一個實際可行的選項。更不用說,從組織面來看,我們正在完成 Gambro 的整合。過去 12 個月,這家公司因為分拆而被大量牽動,分拆一直是第一優先事項,而且確實應該如此。因為我相信回頭看,我們會意識到這個決策為所有利害關係人以及兩家公司的所有股東創造了顯著價值。現在這件事完成了,我們會把注意力重新聚焦到其他優先事項上。但我認為在接下來例如 12 個月內,不太可能出現轉型型交易,因為我們沒有足夠的財務彈性去做。
- Analyst
- Analyst
Thanks so much.
非常感謝。
- VP of IR
- VP of IR
Kathy, this is Claire. We have time for two more questions.
Kathy,我是 Claire。我們還有時間再回答兩個問題。
Operator
Operator
Our next question is from Kristen Stewart with Deutsche Bank, your line is open.
下一個問題來自德意志銀行(Deutsche Bank)的 Kristen Stewart,您的線路已開通。
- Analyst
- Analyst
Thanks for taking the question. Just wanted to go back to Gambro, and just get an understanding on the -- what's changed on the sales growth forecast? Because it seems like you're hitting the metrics from a cost synergies perspective, but the sales growth outlook seems to be very different. It's one that was -- at least at the time of acquisitions, [are supposed] to accelerate the overall growth profile of Baxter as a whole, and obviously, within there, the Medical Products business. And here we are talking about the HD business only growing 2% to 3% over the long-range plan. That was certainly not something that was my impression that was going to be the growth forecast for Gambro at the time of the deal. So, what has really changed about that business or the market, that's really leading that Gambro, or maybe just the market to be a lot slower now versus only a couple of years ago (multiple speakers) for Jay?
謝謝讓我提問。我想回到 Gambro,想了解一下——銷售成長預測方面到底有哪些變化?因為看起來你們在成本綜效的指標上達標了,但銷售成長展望似乎非常不同。這筆交易——至少在收購當時——[原本應該]加速 Baxter 整體的成長輪廓,當然也包括醫療產品事業。但現在我們談的是 HD 業務在長期計畫中只成長 2% 到 3%。這絕對不是我在交易當時對 Gambro 成長預測的印象。所以,這個業務或市場到底發生了什麼改變,導致 Gambro——或許只是市場——相較於幾年前現在變得慢很多?(多位發言者)這題給 Jay?
- Chairman & CEO
- Chairman & CEO
Okay, Kristen, thanks for the question. So let me start at a high level. Okay. I'm really glad we did the Gambro deal. Things always change in big acquisitions, but looking back now,1.5 year on or thereabouts, almost 2 years now, I'm really glad we did the deal. Things always turn out differently than what you anticipate. And you're absolutely right -- it's a follow-on to the commentary I made earlier. I don't know if this was David Lewis or David Roman's question, I can't recall, in terms of the traditional in-center hemo business, okay? Because that has fallen behind what our expectations are, so your commentary in that regard is spot on. I would agree with that.
好的,Kristen,謝謝你的問題。我先從較高層次談起。好的。我真的很高興我們做了 Gambro 這筆交易。大型收購中事情總是會變,但回頭看,1.5 年左右——或差不多——現在接近 2 年了,我真的很高興我們做了這筆交易。結果總是會和你預期的不一樣。而你說得完全正確——這也呼應我先前的評論。我不記得那是 David Lewis 還是 David Roman 的問題,關於傳統院內血液透析(in-center hemo)業務,對吧?因為那一塊確實落後於我們的預期,所以你在這方面的評論非常到位。我同意。
If you take a step back and look at the total deal. First of all, much of the value of the deal -- more so that typically in acquisitions was based upon the cost reduction. And as we commented today, we are well on track to achieve frankly, if not slightly exceed that $300 million target. So that's really positive. In terms of the higher growth, higher margin business, the in-center CRT, that's is moving along totally in accordance with our expectation.
如果你退一步看整筆交易。首先,這筆交易的價值有很大一部分——比一般收購更是如此——是建立在成本降低之上。而正如我們今天所評論的,我們非常按計畫在達成,坦白說甚至可能略微超過 3 億美元的目標。所以這非常正面。至於高成長、高毛利的業務,也就是院內 CRT,那一塊的進展完全符合我們的預期。
The other thing that has been favorable, and I think going forward increasingly, you have to look at the renal performance in aggregate. Part of the rationale was to complete the full product line, thereby enabling us to participate in commercial opportunities, where previously perhaps we didn't, because we didn't have all the clubs in our bag, so to speak in the traditional in-center piece. And so, the commercial synergies that we're getting, particularly on PD and so on have been -- have achieved -- certainly achieved, if not exceeded our expectation.
另一個有利的因素,而且我認為未來會愈來愈重要的是,你必須以整體角度來看腎臟事業的表現。其中一部分的理由是補齊完整產品線,讓我們能參與一些商業機會;過去我們可能無法參與,是因為我們沒有把所有球桿都放在球袋裡——就傳統院內那一塊而言,可以這麼說。因此,我們所取得的商業綜效,特別是在 PD 等方面,已經——確實已經達成,甚至可能超過我們的預期。
The piece that is slower is the traditional in-center piece. Part of it is market driven, and part of it is organizationally driven. I think the integration of the commercial organizations has been more challenging than what we anticipated, bringing the Gambro and the Baxter pieces together, including change-out of -- most of this business, as you know is outside the US. So it is a by-product of 50 general managers around the world, and making sure that the right leaders are in the right place, and in each market. And so, the starting out process in that regard, has been somewhat more challenging than we had anticipated in the modeling. And secondarily, as we've converted from distributors going direct, which is our mode of doing business as you know. While we fully anticipated that as a result of due diligence, there have been some challenges associated with converting from distributors, largely in emerging developing markets, in ways that we didn't anticipate, so it has been slower than we anticipated. That was operationally related.
較慢的部分是傳統院內那一塊。部分原因是市場驅動,部分原因是組織驅動。我認為商業組織的整合比我們預期更具挑戰性,把 Gambro 與 Baxter 的團隊整合在一起,包括更換——如你所知,這項業務大多在美國以外。所以這是全球約 50 位總經理的副產品,要確保每個市場、每個地區都把對的領導者放在對的位置上。因此,在這方面的起步過程,比我們在模型中預期的更具挑戰。其次,當我們從經銷商轉為直營(direct),這是我們一貫的營運模式,如你所知。雖然我們在盡職調查時已完全預期會發生,但在從經銷商轉換的過程中——主要是在新興發展中市場——出現了一些我們未曾預期的挑戰,因此進度比我們預期更慢。這是營運層面的因素。
Then in terms of the market place, frankly, in terms of the pricing it's performing pretty much in accordance with what we modeled. We anticipate in the acquisition analysis, that this was, and we continue to be pricing competitive. We didn't anticipate, perhaps some of the austerity measures. I cited just one recently in France. And the other piece of it is, we have been consistent with our overall priority of new Bax going forward, more discerning and more demanding in terms of returns, through our new mindset of new Baxter. And that's had an impact in terms of some of the profitability. So I touched on a lot of it, but I really -- maybe I'll just end, where I started, Kristin, which is I'm very pleased that we did the deal, for a lot of different reasons, and confident that the value clearly is going to be generated over the long-term.
接著就市場面而言,坦白說,就定價來看,其表現基本上與我們建模的結果相當一致。我們在併購分析中預期如此,而且我們也持續維持具競爭力的定價。我們或許沒有預期到某些緊縮措施。我最近在法國就舉了一個例子。另外一點是,我們一直貫徹我們對未來新 Baxter 的整體優先事項:在回報方面更審慎、要求更高,這是我們「新 Baxter」的新思維。而這也在某種程度上影響了部分獲利能力。所以我談到了很多面向,但我想——也許我就回到一開始的結論,Kristin:我非常高興我們做了這筆交易,原因很多,而且我也有信心,長期來看,價值顯然會被創造出來。
- Analyst
- Analyst
Great. And there's no update on the home hemo dialysis time lines for the US relative to the -- (multiple speakers)
很好。那關於美國家用血液透析的時程,相較於——(多位講者)目前沒有更新嗎?
- Chairman & CEO
- Chairman & CEO
I'll let Claire -- (multiple speakers).
我讓 Claire 來回答——(多位講者)。
- VP of IR
- VP of IR
We obviously announced, we said that filed -- that the FDA has accepted the investigational device exemption. So that allows us to start the US trials, which we continue to expect that will begin before the end of the year, with filing likely sometime in the 2017 time frame, and a launch in 2018, consistent with what we shared at the Investor conference in May.
我們先前已經宣布,我們表示已提交——FDA 已接受該研究用醫療器材豁免(IDE)。因此這讓我們可以啟動美國的試驗;我們仍預期會在年底前開始,並可能在 2017 年某個時間點提出申請,於 2018 年上市,與我們在 5 月投資人會議上分享的內容一致。
- Analyst
- Analyst
Okay. And then for, Jay, just in terms of the Baxalta stake -- sorry if I missed this. Can you comment on how the split will be, in terms of how much will go towards the US pension, I think was about a $1 billion, and how much will go towards paying down debt? Or how much will just go towards acquisitions and whatnot, or just will become cash on the balance sheet? And I think there was something in the -- one of the filings that mentioned a potential stock exchange as well?
好的。接著,Jay,關於 Baxalta 持股——抱歉如果我漏聽了。你能否談談分配會如何進行:有多少會用於美國退休金(我記得大約是 10 億美元),以及有多少會用於償還債務?或者有多少會用於併購等用途,或只是成為資產負債表上的現金?另外我想在——某份申報文件中也提到可能會有股票交換?
- CFO
- CFO
So yes. Kristen, there is really three uses for the retained stake, pension, a stock for stock exchange or split off [under the terms], and a stock for debt exchange, which essentially amounts to a secondary offering, coupled with a debt buyback. So, those are the three vehicles that we're currently evaluating. Each of them, to the extent that we pursue them, within 18 month window are tax-free uses of the stake. So what we've said is, we expect a 50 basis point benefit from contributions to the pension, which would imply approximately a $600 million contribution to the pension. But frankly, the sizing of that ultimate contribution will very much depend upon the prevailing interest rate environment. We don't want to go well north of 100% funded status. As we said today, we are roughly 80%. And so, this would close a portion of that gap, but it wouldn't close all the gap. To the extent that interest rates rise, between now and year end when we would contemplate a transaction of this nature, we're going to watch that very carefully.
是的。Kristen,保留持股的用途其實有三種:退休金、以股換股的交換或分拆(依條款),以及以股換債的交換,本質上相當於二次發行搭配回購債務。所以,這是我們目前正在評估的三種工具。其中每一種,只要我們在 18 個月的窗口期內推進,都是該持股的免稅使用方式。因此我們說過,我們預期對退休金提撥可帶來 50 個基點的效益,這意味著約 6 億美元的退休金提撥。但坦白說,最終提撥規模將高度取決於當時的利率環境。我們不希望資金提撥後的提存狀態遠高於 100%。如同我們今天所說,我們目前大約是 80%。因此這會縮小部分缺口,但不會完全補足。若利率在現在到年底(我們可能考慮進行此類交易的時間點)之間上升,我們會非常密切地觀察。
As a relates to the other two pieces, it's really going to depend upon our ability to execute those transactions, with the least amount of cost. Because to the extent that we over delever, we always have the opportunity to lever back up to buy shares, or to pursue M&A. The important thing is, we want to use this retained stake -- with the limited -- with the least amount of economic loss to Baxter. So that we're going to be very thoughtful about transaction costs, and premiums and things of that nature.
至於另外兩個部分,主要將取決於我們以最低成本執行這些交易的能力。因為如果我們去槓桿過度,我們隨時都有機會再加槓桿來回購股票,或推動併購。重點是,我們希望運用這筆保留持股——以對 Baxter 造成最小的經濟損失。因此我們會非常審慎地考量交易成本、溢價以及諸如此類的因素。
- Analyst
- Analyst
Yes, okay. Thank you.
是的,好的。謝謝。
Operator
Operator
Our final question comes from Josh Jennings from Cowen and Company, your line is open.
我們最後一個問題來自 Cowen and Company 的 Josh Jennings,您的線路已開通。
- Analyst
- Analyst
Good evening, thanks a lot. Just wanted -- a quick question on operating margin front. Can you talk about the operating margin baseline and trajectories for the four business units, relative to the corporate margins? Or are there one or two units that have more depressed margins, where you can give us some more specifics, or granularity on how the margin turnaround can be achieved?
晚安,非常感謝。我想問——關於營業利益率的一個簡短問題。你能否談談四個事業單位的營業利益率基準與走勢,相對於公司整體利益率的情況?或者是否有一到兩個單位的利益率較為低迷,你能提供更具體或更細的說明,談談如何達成利益率的改善?
- CFO
- CFO
We really haven't disclosed margins by segment or area, except to say that there are certain businesses that carry a higher margin than the Baxter average, and those businesses include the CRT business, our surgical care business, our nutrition business within the integrated pharmacy systems. Those are a few of the businesses which carry a higher margin than the corporate average. In the case of those businesses, our full expectation is to grow them as fast as we can, with promotional investments to support that. By doing that, we expect to see a positive benefit on the margin. There are other categories of businesses which we characterize as having lower margins. And what we've said is, it really not a global question to ask, but it's more specific than that. In certain products, in certain geographies, we have margins that are below our corporate target. With respect to those businesses, our expectations are, we either are going to fix, shrink, or exit those businesses over time. So we have a very disciplined framework in place, but it's a more fine-tuned methodology, then a global methodology with businesses that have lower margins or higher margins. Because frankly, in some businesses that may have a lower margin in one market, that margin maybe dramatically different in another market, depending on the nature of the dynamic.
我們其實沒有按事業別或區域揭露利益率,僅表示某些業務的利益率高於 Baxter 的平均水準;這些業務包括 CRT 業務、我們的外科照護業務、以及整合式藥局系統中的營養業務。以上是幾個利益率高於公司平均的業務。對於這些業務,我們完全預期會在可行範圍內盡快擴張,並投入促銷性投資來支持成長。透過這樣做,我們預期會對利益率帶來正面效益。另外也有一些業務類別,我們將其歸類為較低利益率。而我們所說的是,這不是一個可以用「整體」來回答的問題,而是更具體。在某些產品、某些地理區域,我們的利益率低於公司目標。對於這些業務,我們的預期是:隨時間推進,我們要嘛修復、要嘛縮減、要嘛退出。因此我們有一套非常嚴謹的框架,但它是更精細的做法,而不是用「低利益率或高利益率」的全球性方法一概而論。因為坦白說,有些業務在某個市場可能利益率較低,但在另一個市場可能因動態不同而有顯著差異。
- Analyst
- Analyst
Great. And just on that portfolio optimization point that you brought up. Can you talk about the pace of product pruning or exiting sub-optimal geographies. You've already started in renal. It sounds like you do have strategic plans in place, but is this going to depend on balancing this portfolio optimization, and then loss of revenues, and how that flows down to the bottom line?
很好。另外就你提到的投資組合優化這點。你能談談產品精簡或退出次優地理市場的速度嗎?你們已經在腎臟領域開始了。聽起來你們確實已有策略計畫,但這是否會取決於在投資組合優化與營收流失之間取得平衡,以及這如何傳導到最終損益?
- CFO
- CFO
Yes. So we completed the portfolio analysis. We have a clear line of sight to the fully-loaded profitability and the economic returns of our businesses. But before we exit a business, our first expectation is that our general managers will attempt to fix it, and that takes some time in certain instances. So the pace at which we do this, will really be gated by how successful we are in turning around some of these businesses, or not. And to the extent that we're not, we will make very clear and definitive decisions about exit. But only after we've given the opportunity to the operations team to actually fix that business. Bob, I don't know if you want to anything?
是的。所以我們已完成投資組合分析。我們對各項業務的全額負擔獲利能力與經濟回報有清楚的掌握。但在退出某項業務之前,我們的第一個期待是各事業總經理會先嘗試把它修復,而在某些情況下這需要一些時間。因此我們推進的速度,將主要取決於我們能否成功扭轉其中一些業務——或無法扭轉。若確實無法扭轉,我們就會做出非常清楚且明確的退出決策。但那會是在我們先給營運團隊機會去真正修復該業務之後。Bob,我不知道你是否想補充什麼?
- Chairman & CEO
- Chairman & CEO
All I would say, but that's not going to be a protracted period of time. There will be a sense of urgency in this, but there is a disciplined process as Jay described.
我只想說,這不會拖得太久。我們會有緊迫感,但也會如 Jay 所述,遵循一個有紀律的流程。
- Analyst
- Analyst
Excellent. Thank you very much.
非常好。非常感謝。
Operator
Operator
Ladies and gentlemen, this concludes today's conference call with Baxter International. Thank you for participating. You may now disconnect.
各位女士、先生,今天 Baxter International 的電話會議到此結束。感謝各位參與。您現在可以掛線。